Zanamivir
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Zanamivir, better known as Relenza, ([[____]])"/> | <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Zanamivir, better known as Relenza, ([[____]])"/> | ||
===Better Known as: Relenza=== | ===Better Known as: Relenza=== | ||
| - | * Marketed By: | + | * Marketed By: GlaxoSmithKline |
* Major Indication: [[Influenza]] Infection | * Major Indication: [[Influenza]] Infection | ||
* Drug Class: [[Neuraminidase]] Inhibitor | * Drug Class: [[Neuraminidase]] Inhibitor | ||
* Date of FDA Approval: | * Date of FDA Approval: | ||
| - | * | + | * 2009 Sales:$1.1 Billion |
* Importance: | * Importance: | ||
* See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | * See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | ||
Revision as of 11:14, 12 December 2010
|
Better Known as: Relenza
- Marketed By: GlaxoSmithKline
- Major Indication: Influenza Infection
- Drug Class: Neuraminidase Inhibitor
- Date of FDA Approval:
- 2009 Sales:$1.1 Billion
- Importance:
- See Pharmaceutical Drugs for more information about other drugs and diseases.
Mechanism of Action
Pharmacokinetics
For References to Pharmacokinetic data, see: References |
||||||||||||||||||||||||||||||||||||||||||
References
